title: Lucinactant for the prevention of respiratory distress syndrome in premature infants.
abstract: Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS.
authors.affiliation: Department of Pediatrics & Communicable Diseases, Division of Neonatal-Perinatal Medicine, CS Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI 48109, USA.
authors.forename: Brian K
authors.initials: BK
authors.lastname: Jordan
authors.forename: Steven M
authors.initials: SM
authors.lastname: Donn
mesh_terms: D004338:Drug Combinations; D005233:Fatty Alcohols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D023421:Models, Animal; D010715:Phosphatidylglycerols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011506:Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000401:mortality / Q000517:prevention & control*
chemical_list: D004338:Drug Combinations; D005233:Fatty Alcohols; D010715:Phosphatidylglycerols; D011506:Proteins; D011663:Pulmonary Surfactants; C502722:lucinactant